Publications
We maintain a culture of scientific excellence and will continue to drive future innovation through sharing our key findings in a peer reviewed format
Discoveries and developments making mRNA powerful enough to serve as medicine
The picture above is showing the cover of the peer-reviewed journal Blood in which the BioNTech co-founders’ first mRNA-related publication entitled “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells” was published in 2006. Since the late 1990, they began a systematic discovery and optimization process to solve the basic problems of RNA: low and short-lived protein production. The 2006 publication was followed by a series of articles in the years 2007 to 2010 describing additional improvements of the mRNA backbone. The systematic principles for mRNA vaccine design introduced by Sahin and Türeci became the widely used standard for optimizing vector scaffolds for mRNA therapy. Discoveries and developments making mRNA powerful enough to serve as medicine.
mRNA technology
- Beck J, Diken M, Suchan M, Streuber M, Diken E, Kolb L, Allnoch L, Vascotto F, Peters D, Beissert T, Akilli-Özturk Ö, Türeci Ö, Kreiter S, Vormehr M, Sahin U.
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers.
Cancer Cell, 2024
- Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Müller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Łuksza M, Cohen N, Tang L, Basturk O, Gönen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Türeci Ö, Greenbaum BD, Jarnagin WR, Drebin J, O'Reilly EM, Balachandran VP.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Nature, 2023
- Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U.
Identification of neoantigens for individualized therapeutic cancer vaccines.
Nature Reviews Drug Discovery, 2022
- Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, Petschenka J, Diken M, Kreiter S, Türeci Ö, Sahin U, Vascotto F
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer.
Cancer Immunology, 2022
- Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, Hsu K, Bernardo M, Karikó K, Kreiter S, Kuhn AN, Levit M, Malkova N, Masciari S, Pollard J, Qu H, Ryan S, Selmi A, Schlereth J, Singh K, Sun F, Tillmann B, Tolstykh T, Weber W, Wicke L, Witzel S, Yu Q, Zhang YA, Zheng G, Lager J, Nabel GJ, Sahin U, Wiederschain D.
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.
Science Translational Medicine, 2021
- Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM
mRNA therapeutics in cancer immunotherapy.
Science Translational Medicine, 2021
- Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, Kranz LM, Diken M, Kreiter S, Haas H, Attig S, Rae R, Cuk K, Kemmer-Brück A, Breitkreuz A, Tolliver C, Caspar J, Quinkhardt J, Hebich L, Stein M, Hohberger A, Vogler I, Liebig I, Renken S, Sikorski J, Leierer M, Müller V, Mitzel-Rink H, Miederer M, Huber C, Grabbe S, Utikal J, Pinter A, Kaufmann R, Hassel JC, Loquai C & Türeci Ö
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Nature, 2020
- Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Nature, 2017
- Melief CJM
Cancer: Precision T-cell therapy targets tumours
Nature, 2017
- Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.
Nature Medicine, 2017
- Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D.
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.
Nature, 2017
- Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U.
Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
Nanomedicine (Lond), 2016
- Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U.
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Nature, 2016
- Poleganov MA, Eminli S, Beissert T, Herz S, Moon JI, Goldmann J, Beyer A, Heck R, Burkhart I, Barea Roldan D, Türeci Ö, Yi K, Hamilton B, Sahin U
Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.
Human Gene Therapy, 2015
- Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrors B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Nature, 2015
- Kowalska J, Wypijewska del Nogal A, Darzynkiewicz ZM, Buck J, Nicola C, Kuhn AN, Lukaszewicz M, Zuberek J, Strenkowska M, Ziemniak M, Maciejczyk M, Bojarska E, Rhoads RE, Darzynkiewicz E, Sahin U, Jemielity J
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.
Nucleic Acids Research, 2014
- Sahin U, Kariko K and Tureci O
mRNA-based therapeutics–developing a new class of drugs.
Nature Reviews Drug Discovery, 2014
- Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.
BMC Genomics, 2014
- Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Türeci O, Sahin U
Exploiting the mutanome for tumor vaccination.
Cancer Research, 2012
- Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C., Türeci, Ö. & Sahin, U.
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.
Gene Therapy, 2011
- Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O and Sahin U.
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.
Cancer Research, 2010
- Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, O. & Sahin, U.
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.
Gene Therapy, 2010
- Kreiter, Sebastian, Selmi, Abderraouf, Diken, Mustafa, Sebastian, Martin, Osterloh, Phillip, Schild, Hansjörg, Huber, Christoph, Türeci, Özlem & Sahin, Ugur.
Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.
Journal of Immunology, 2008
- Holtkamp, Silke, Kreiter, Sebastian, Selmi, Abderraouf, Simon, Petra, Koslowski, Michael, Huber, Christoph, Türeci, Özlem & Sahin, Ugur.
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.
Blood, 2006
- Simões EAF, Klein NP, Sabharwal C, Gurtman A, Kitchin N, Ukkonen B, et al.
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5–11-Year-Olds.
Journal of the Pediatric Infectious Diseases Society, 2023
- Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
New England Journal of Medicine, 2023
- Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, et al.
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years.
New England Journal of Medicine, 2023
- Muik A, Lui BG, Bacher M, Wallisch A-K, Toker A, Couto CIC, et al.
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice. Vol. 7, Science Immunology.
Science Immunology, 2022
- Hui A-M, Li J, Zhu L, Tang R, Ye H, Lin M, et al.
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
The Lancet Regional Health, 2022
- Muik A, Lui BG, Bacher M, Wallisch A-K, Toker A, Finlayson A, et al.
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
Science Immunology, 2022
- Quandt J, Muik A, Salisch N, Lui BG, Lutz S, Krüger K, et al.
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes.
Science Immunology, 2022
- Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al.
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
New England Journal of Medicine, 2022
- Thomas, Perez, Lockhart, Hariharan, Kitchin, Bailey, et al.
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
Vaccine, 2022
- McLean G, Kamil J, Lee B, Moore P, Schulz TF, Muik A, et al.
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.
mBio, 2022
- Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
New England Journal of Medicine, 2022
- Haranaka M, Baber J, Ogama Y, Yamaji M, Aizawa M, Kogawara O, et al.
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.
Nature Communications, 2021
- Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
New England Journal of Medicine, 2021
- Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al.
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
New England Journal of Medicine, 2021
- Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, Huppert A.
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
New England Journal of Medicine, 2021
- Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group.
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
New England Journal of Medicine, 2021
- Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, Cutler M, Cooper D, Muik A, Jansen KU, Sahin U, Xie X, Dormitzer PR, Shi PY
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Nature, 2021
- Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Nature, 2021
- Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, et al.
Safety and immunogenicity of the SARS-COV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
Nature Medicine, 2021
- Liu, Y. et al.
Neutralizing Activity of BNT162b2-Elicited Serum
New England Journal of Medicine, 2021
- Annette B. Vogel, Isis Kanevsky, Ye Che, Kena A. Swanson, Alexander Muik, Mathias Vormehr, Lena M. Kranz, Kerstin C. Walzer, Stephanie Hein, Alptekin Güler, Jakob Loschko, Mohan S. Maddur, Ayuko Ota-Setlik, Kristin Tompkins, Journey Cole, Bonny G. Lui, Thomas Ziegenhals, Arianne Plaschke, David Eisel, Sarah C. Dany, Stephanie Fesser, Stephanie Erbar, Ferdia Bates, Diana Schneider, Bernadette Jesionek, Bianca Sänger, Ann-Kathrin Wallisch, Yvonne Feuchter, Hanna Junginger, Stefanie A. Krumm, André P. Heinen, Petra Adams-Quack, Julia Schlereth, Stefan Schille, Christoph Kröner, Ramón de la Caridad Güimil Garcia, Thomas Hiller, Leyla Fischer, Rani S. Sellers, Shambhunath Choudhary, Olga Gonzalez, Fulvia Vascotto, Matthew R. Gutman, Jane A. Fontenot, Shannan Hall-Ursone, Kathleen Brasky, Matthew C. Griffor, Seungil, Andreas A. H. Su, Joshua A. Lees, Nicole L. Nedoma, Ellene H. Mashalidis, Parag V. Sahasrabudhe, Charles Y. Tan, Danka Pavliakova, Guy Singh, Camila Fontes-Garfias, Michael Pride, Ingrid L. Scully, Tara Ciolino, Jennifer Obregon, Michal Gazi, Ricardo Carrion Jr, Kendra J. Alfson, Warren V. Kalina, Deepak Kaushal, Pei-Yong Shi, Thorsten Klamp, Corinna Rosenbaum, Andreas N. Kuhn, Özlem Türeci, Philip R. Dormitzer, Kathrin U. Jansen & Ugur Sahin
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Nature, 2021
- Xuping Xie, Yang Liu, Jianying Liu, Xianwen Zhang, Jing Zou, Camila R. Fontes-Garfias, Hongjie Xia, Kena A. Swanson, Mark Cutler, David Cooper, Vineet D. Menachery, Scott C. Weaver, Philip R. Dormitzer & Pei-Yong Shi
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Nature Medicine, 2021
- Muik A, Wallisch AK, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci Ö, Dormitzer PR, Şahin U.
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
Science, 2021
- Fernando P. Polack, M.D., Stephen J. Thomas, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Pérez Marc, M.D., Edson D. Moreira, M.D., Cristiano Zerbini, M.D., Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., Satrajit Roychoudhury, Ph.D., Kenneth Koury, Ph.D., Ping Li, Ph.D., Warren V. Kalina, Ph.D., David Cooper, Ph.D., Robert W. Frenck, Jr., M.D., Laura L. Hammitt, M.D., Özlem Türeci, M.D., Haylene Nell, M.D., Axel Schaefer, M.D., Serhat Ünal, M.D., Dina B. Tresnan, D.V.M., Ph.D., Susan Mather, M.D., Philip R. Dormitzer, M.D., Ph.D., Uğur Şahin, M.D., Kathrin U. Jansen, Ph.D., and William C. Gruber, M.D., for the C4591001 Clinical Trial Group
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine, 2020
- Edward E. Walsh, M.D., Robert W. Frenck, Jr., M.D., Ann R. Falsey, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., Kathleen Neuzil, M.D., Mark J. Mulligan, M.D., Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., Ping Li, Ph.D., Kenneth Koury, Ph.D., Warren Kalina, Ph.D., David Cooper, Ph.D., Camila FontesGarfias, B.Sc., PeiYong Shi, Ph.D., Özlem Türeci, M.D., Kristin R. Tompkins, B.Sc., Kirsten E. Lyke, M.D., Vanessa Raabe, M.D., Philip R. Dormitzer, M.D., Kathrin U. Jansen, Ph.D., Uğur Şahin, M.D., and William C. Gruber, M.D.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
New England Journal of Medicine, 2020
- Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz, Mathias Vormehr, Alina Baum, Kristen Pascal, Jasmin Quandt, Daniel Maurus, Sebastian Brachtendorf, Verena Lörks, Julian Sikorski, Rolf Hilker, Dirk Becker, Ann-Kathrin Eller, Jan Grützner, Carsten Boesler, Corinna Rosenbaum, Marie-Cristine, Kühnle, Ulrich Luxemburger, Alexandra Kemmer-Brück, David Langer, Martin Bexon, Stefanie Bolte, Katalin Karikó, Tania Palanche, Boris Fischer, Armin Schultz, Pei-Yong Shi, Camila Fontes-Garfias, John L. Perez, Kena A. Swanson, Jakob Loschko, Ingrid L. Scully, Mark Cutler, Warren Kalina, Christos A. Kyratsous, David Cooper, Philip R. Dormitzer, Kathrin U. Jansen & Özlem Türeci
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Nature, 2020
- Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Vanessa Raabe, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei-Yong Shi, Özlem Türeci, Kristin R. Tompkins, Edward E. Walsh, Robert Frenck, Ann R. Falsey, Philip R. Dormitzer, William C. Gruber, Uğur Şahin & Kathrin U. Jansen
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Nature, 2020
- Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Öztürk Ö, Kranz LM, Berger H, Petschenka J, Diken M, Kreiter S, Yogev N, Waisman A, Karikó K, Türeci Ö, Sahin U.
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
Science, 2021
Engineered Cell Therapies
- K.Reinhard, B. Rengstl, P. Oehm, K. Michel, A. Billmeier, N. Hayduk, O. Klein, K. Kuna, Y. Ouchan, S.Wöll, E. Christ, D. Weber, M. Suchan, T. Bukur, M. Birtel, V. Jahndel, K. Mroz, K. Hobohm, L. Kranz, M.Diken, K. Kühlcke, Ö. Türeci, U. Sahin
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Science, 2020
- Omokoko T, Simon P, Tureci O and Sahin U.
Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.
Oncoimmunology, 2015
- Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K et al (2014).
Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
Cancer Immunology Research, 2014
Protein-based Therapeutics
- Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö.
Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
Journal of Cancer Research and Clinical Oncology, 2023
- Kopetz S, Morris VK, Alonso-Orduña V, Garcia-Alfonso P, Reboredo M, Fernandez Montes A, et al.
A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting.
Journal of Clinical Oncology, 2022
- Schumacher J, Bacic T, Staritzbichler R, Daneschdar M, Klamp T, Arnold P, Jägle S, Türeci Ö, Markl J and Sahin U.
Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.
Journal of Nanobiotechnology, 2018
- Christiane R Stadler, Hayat Bähr-Mahmud, Laura M Plum, Kathrin Schmoldt, Anne C Kölsch, Özlem Türeci & Ugur Sahin.
Characterization of the First-in-Class T-Cell Engaging Bispecific Single-Chain Antibody for Targeted Immunotherapy of Solid Tumors Expressing the Oncofetal Protein Claudin 6.
OncoImmunology, 2015
- Klamp T, Schumacher J, Huber G, Kuhne C, Meissner U, Selmi A, Hiller T, Kreiter S, Markl J, Tureci O, et al.
Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases.
Cancer Research, 2011
- Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H.
Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta.
Journal of Molecular Biology, 2010
- Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Wentzel A, Frauendorf H, Sommerhoff CP, Diederichsen U, Kolmar H.
Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis.
Chembiochem, 2008
- Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. (2007).
Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists.
FEBS Journal, 2007
Small Molecule Immunomodulators
- Vascotto F, Petschenka J, Walzer KC, Vormehr M, Brkic M, Strobl S, Rösemann R, Diken M, Kreiter S, Türeci Ö, Sahin U.
Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.
Oncoimmunology, 2019
